BioCentury | Apr 9, 2021
Translation in Brief

Two ways to reverse CAR T cell exhaustion; plus a ligand and its receptor in a single vector, Cleave, Amazentis and Cello

...protein levels. The second is dependent on transient exposure to kinase inhibitor Sprycel dasatinib from Bristol Myers Squibb Co....
...– Toll-like receptor 7TLR8 – Toll-like receptor 8 Danielle Golovin Sprycel, dasatinib (BMS-354825) CB-5339 Stanford University Lyell Immunopharma Inc. Obsidian Therapeutics Inc. Bristol Myers Squibb Co. University...
BioCentury | Apr 8, 2021
Finance

With $95M second fund and incubator, Japan-focused Remiges helps start-ups take flight

...Pharma Co. Ltd., Senju Pharmaceutical Co. Ltd., and Bristol Myers Squibb Co....
BioCentury | Apr 7, 2021
Management Tracks

Takeda’s Koo to lead Overland-ADC joint venture; plus Precision, Amryt, Bridge, Opthea and Cogent

...the region. Frame held several senior leadership roles at Novartis AG (NYSE:NVS; SIX:NOVN), Sandoz Ltd., Bristol Myers Squibb Co....
BioCentury | Apr 3, 2021
Management Tracks

Biotech CEOs in China: a broadening talent pool

...OrbiMed Advisors in September. Prior to joining BioShin, Lintel was president and general manager of Bristol Myers Squibb Co....
BioCentury | Apr 3, 2021
Deals

April 2 Quick Takes: Agios begins share buybacks upon closing Servier deal, plus Royalty-GSK, Gracell-Lonza, Alloy, Eloxx-Zikani and Angelini-Ovid

...announced plans to repurchase 7.1 million shares, or $344.5 million, of Agios stock held by Bristol Myers Squibb Co....
BioCentury | Apr 2, 2021
Management Tracks

BeiGene unveils new CFO; plus Precigen, Alphamab, Flagship, Melinta, Immunome and more

...oncology teams at Natera Inc. (NASDAQ:NTRA), Inovio Pharmaceuticals Inc. (NASDAQ:INO), Astellas Pharma Inc. (Tokyo:4503) and Bristol Myers Squibb Co....
BioCentury | Apr 1, 2021
Management Tracks

Remembering Gilead’s John Martin, whose therapies saved ‘millions’

...stints at Syntex Corp. and Bristol Myers Squibb Co. (NYSE:BMY), then Bristol-Myers...
...seeds in a deal Martin did at Bristol-Myers...
BioCentury | Mar 27, 2021
Regulation

FDA approval solidifies bluebird’s anti-BCMA CAR T as ‘cornerstone’ of BMS’s multiple myeloma portfolio

...or two-thirds, of its global 2020 sales. As Bristol Myers Squibb Co....
...JCAR017) bb21217 Ciltacabtagene autoleucel (JNJ-68284528, JNJ-4528, LCAR-B38M) bluebird bio Inc. GlaxoSmithKline plc Bristol Myers Squibb Co. Johnson...
BioCentury | Mar 26, 2021
Product Development

Next-generation checkpoint development surges as rare wins overshadow setbacks

...Thursday’s announcement that anti-LAG3 mAb relatlimab from Bristol Myers Squibb Co....
BioCentury | Mar 26, 2021
Finance

As valuation swells above $380M, Syncona-backed Gyroscope draws $148M series C, mulls listing

...finance and operations at MyoKardia Inc., which Bristol Myers Squibb Co....
Items per page:
1 - 10 of 6985
BioCentury | Apr 9, 2021
Translation in Brief

Two ways to reverse CAR T cell exhaustion; plus a ligand and its receptor in a single vector, Cleave, Amazentis and Cello

...protein levels. The second is dependent on transient exposure to kinase inhibitor Sprycel dasatinib from Bristol Myers Squibb Co....
...– Toll-like receptor 7TLR8 – Toll-like receptor 8 Danielle Golovin Sprycel, dasatinib (BMS-354825) CB-5339 Stanford University Lyell Immunopharma Inc. Obsidian Therapeutics Inc. Bristol Myers Squibb Co. University...
BioCentury | Apr 8, 2021
Finance

With $95M second fund and incubator, Japan-focused Remiges helps start-ups take flight

...Pharma Co. Ltd., Senju Pharmaceutical Co. Ltd., and Bristol Myers Squibb Co....
BioCentury | Apr 7, 2021
Management Tracks

Takeda’s Koo to lead Overland-ADC joint venture; plus Precision, Amryt, Bridge, Opthea and Cogent

...the region. Frame held several senior leadership roles at Novartis AG (NYSE:NVS; SIX:NOVN), Sandoz Ltd., Bristol Myers Squibb Co....
BioCentury | Apr 3, 2021
Management Tracks

Biotech CEOs in China: a broadening talent pool

...OrbiMed Advisors in September. Prior to joining BioShin, Lintel was president and general manager of Bristol Myers Squibb Co....
BioCentury | Apr 3, 2021
Deals

April 2 Quick Takes: Agios begins share buybacks upon closing Servier deal, plus Royalty-GSK, Gracell-Lonza, Alloy, Eloxx-Zikani and Angelini-Ovid

...announced plans to repurchase 7.1 million shares, or $344.5 million, of Agios stock held by Bristol Myers Squibb Co....
BioCentury | Apr 2, 2021
Management Tracks

BeiGene unveils new CFO; plus Precigen, Alphamab, Flagship, Melinta, Immunome and more

...oncology teams at Natera Inc. (NASDAQ:NTRA), Inovio Pharmaceuticals Inc. (NASDAQ:INO), Astellas Pharma Inc. (Tokyo:4503) and Bristol Myers Squibb Co....
BioCentury | Apr 1, 2021
Management Tracks

Remembering Gilead’s John Martin, whose therapies saved ‘millions’

...stints at Syntex Corp. and Bristol Myers Squibb Co. (NYSE:BMY), then Bristol-Myers...
...seeds in a deal Martin did at Bristol-Myers...
BioCentury | Mar 27, 2021
Regulation

FDA approval solidifies bluebird’s anti-BCMA CAR T as ‘cornerstone’ of BMS’s multiple myeloma portfolio

...or two-thirds, of its global 2020 sales. As Bristol Myers Squibb Co....
...JCAR017) bb21217 Ciltacabtagene autoleucel (JNJ-68284528, JNJ-4528, LCAR-B38M) bluebird bio Inc. GlaxoSmithKline plc Bristol Myers Squibb Co. Johnson...
BioCentury | Mar 26, 2021
Product Development

Next-generation checkpoint development surges as rare wins overshadow setbacks

...Thursday’s announcement that anti-LAG3 mAb relatlimab from Bristol Myers Squibb Co....
BioCentury | Mar 26, 2021
Finance

As valuation swells above $380M, Syncona-backed Gyroscope draws $148M series C, mulls listing

...finance and operations at MyoKardia Inc., which Bristol Myers Squibb Co....
Items per page:
1 - 10 of 6985